Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Shareholders to Contact the Firm!

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Walgreens business and prospects, resulting in its stock trading at inflated prices.

WBA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Walgreens Boots Alliance is planning to scale down its operations. Its major growth campaign looks to be stalled, at least for now.

3 Things You Need to Know if You Buy Walgreens Boots Alliance Stock Today

NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Shareholders to Contact the Firm!

Lululemon Athletica

Markets are testing all-time highs, but not every stock is performing well. One of these stocks looks like the market's best bargain right now.

Is It Time to Buy 2024's Worst-Performing S&P 500 Stocks?

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Walgreens Boots Alliance Inc Are Urged By The Schall Law Firm To Participate In The Probe Of Potential Securities Fraud

SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024, inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v. Walgreens Boots Alliance, Inc., No. 24-cv-05907 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens and certain of Walgreens' top executives with violations of the Securities Exchange Act of 1934.

WBA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Super Micro Computer

The change reflects the sharp decline in Walgreens' market value this year and the surge in Super Micro's stock price.

Super Micro to Join the Nasdaq 100. Walgreens Gets the Boot.

Altria

Vale S.A.

If cash flow is most important to your financial or investment strategy, finding dividend stocks with the highest yields is likely a top priority. But I'd warn prospective income investors to avoid specific sectors, even if the yields seem top-notch.

3 Dividend Stocks With the Highest Yields in the World

Healthcare Realty Trust Inc

Pfizer

TFS Financial

24/7 Insights Dividend stocks for many reasons often end up as value stocks and that spells opportunity.

Buy These 5 Beaten-Down High-Yield Stocks Before It's Too Late

WBA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead the Walgreens Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Walgreens Boots Alliance Inc Investors Are Encouraged By The Schall Law Firm To Join The Investigation Of Possible Securities Fraud

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive . You are hereby notified that the class action lawsuit Rizwan Bhaila v.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Walgreens Boots Alliance, Inc. Securities and Sets a Lead Plaintiff Deadline of September 10, 2024

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Walgreens Boots Alliance, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - WBA

CVR Energy

New Fortress Energy

PayPal

Warner Bros Discovery Inc

XP Investimentos

In the stock market, finding stocks at 52-week lows with the potential to yield massive price returns is a way to capitalize on undervalued assets. Certain companies hold solid fundamental strengths and strategic adaptations that extend beyond current market sentiments.

7 Stocks at 52-Week Lows to Snag Before They Soar

NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Walgreens Boots Alliance, Inc. (WBA)

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

WBA Shareholders Are Welcomed By The Schall Law Firm To Join The Suspected Securities Fraud Investigation At Walgreens Boots Alliance Inc

Levi & Korsinsky Announces an Investigation on Behalf of Walgreens Boots Alliance, Inc. (WBA) Shareholders Who May Have Been Affected by Fraud

ATTENTION Walgreens Boots Alliance, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK CITY, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Investors to Contact the Firm!

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of William H. Shrank, M.D., to the company's board of directors. Dr. Shrank is globally recognized for his leadership and expertise in healthcare strategy, policy and population health. He joins the WBA board at an important time as the company strengthens its business. Currently, Dr. Shrank is a venture partner with the Bio + Health Team of Andreesen Horowitz, a private venture capita.

Walgreens Boots Alliance Appoints William H. Shrank, M.D.

Investing in the stock market can be daunting, but finding once-in-a-lifetime stocks can offer considerable rewards. Here, the exploration concentrates on three such stocks with high growth potential.

3 Once-in-a-Lifetime Stocks to Buy Now: July 2024

NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Levi & Korsinsky Reminds Walgreens Boots Alliance, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - WBA

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites WBA Shareholders To Participate In The Alleged Securities Fraud Probe At Walgreens Boots Alliance Inc

Chewy

Cintas Corp

DoorDash

Samsara

Cloudflare

UiPath

Taiwan Semiconductor Manufacturing

Unity Software

What's the point of New Year's resolutions if you aren't checking in on them? Goals are ineffective if they're just a ‘set it and forget it' task to do at the end of December. The same can be said for stock picks, like the 12 we unveiled in December. At the end of the first quarter, we checked in on their performance and tried to piece together a road map for the technical performance for rest of 2024.

News for Walgreens Stock (WBA)